Cardiovascular diseases are irreversible. So, it is crucial to prevent them before they appear.
Order your kit today and find out if you are developing a cardiovascular disease before it is too late.
ABOUT US
SPINOVIT is a spin-off of UCLouvain funded in January 2022 by Dr Ir Nancy Van Overstraeten with Vives, B2start and SRIW as investment partners.
The product and service were developed in the laboratory of Prof. Jean-Luc Balligand, Institute of Experimental and Clinical Research from UCLouvain.
The Walloon Region supported the creation of the spin-off with a First Spin-Off grant and the proof of concept through the support to our clinical trial PICA, designed by Dr Ir Nancy Van Overstraeten, demonstrating the predictability of our biomarker.
In July 2023, the results from the PICA trial were issued by the Spinovit team: see tab "Our Proof-Of-Concept study" (publication in preparation). The results were reviewed and confirmed by our Scientific Advisory Board chaired by Prof. JL Balligand.
In August 2023, the supporting initial investors decided to abandon their support to Spinovit.
THE TEAM
Nancy Van Overstraeten
Founder &
Managing Director
Jean-Luc Balligand
Scientific Advisory Board
Arvind
Soni
EPR operator
Jérôme
Linden
Clinical Trial Manager
Nathalie Fabian
EPR technician
TESTIMONIALS
"Finally, something to prevent the cardiovascular diseases"
Guy S.
"Security is just 1 mL of blood away."
Jeanine R.
"I feel safe again"
Albert V.
CONTACT
Spinovit ended its activity in September 2023.
For any enquiry, please contact the former CEO at: nancy@vanover.be
Any correspondence can be addressed to:
VanOver
32, chemin des Roches,
1370 Dongelberg
Belgium
Thank you for your support!
